Merus (NASDAQ:MRUS) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS - Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $85.00 price objective on the biotechnology company's stock.

A number of other analysts have also weighed in on the company. William Blair reaffirmed an "outperform" rating on shares of Merus in a research report on Friday, February 28th. Needham & Company LLC cut their price target on Merus from $85.00 to $83.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Guggenheim reiterated a "buy" rating on shares of Merus in a research note on Wednesday, February 12th. Piper Sandler initiated coverage on Merus in a research report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price objective for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Merus in a report on Thursday, November 21st. They issued a "buy" rating and a $73.00 target price on the stock. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $85.77.

Merus Trading Down 0.4 %

Merus stock traded down $0.19 during midday trading on Monday, reaching $46.10. 459,783 shares of the stock traded hands, compared to its average volume of 638,816. The firm has a market cap of $3.16 billion, a PE ratio of -11.67 and a beta of 1.11. The company has a 50-day simple moving average of $42.22 and a two-hundred day simple moving average of $46.65. Merus has a 12-month low of $37.77 and a 12-month high of $61.61.

Remove Ads

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. The business had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Equities research analysts anticipate that Merus will post -3.85 earnings per share for the current year.

Institutional Trading of Merus

A number of hedge funds and other institutional investors have recently made changes to their positions in MRUS. Polar Asset Management Partners Inc. acquired a new position in Merus during the fourth quarter worth approximately $1,318,000. GF Fund Management CO. LTD. acquired a new position in shares of Merus in the 4th quarter valued at $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Merus by 17.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company's stock valued at $4,152,000 after acquiring an additional 14,544 shares during the period. Woodline Partners LP raised its position in Merus by 0.3% in the 4th quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company's stock valued at $49,977,000 after purchasing an additional 3,593 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Merus during the 4th quarter worth $817,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.